Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2507

Shown on this page

Current sort

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Cleveland Clinic

Stored official records

Open in full search

Conditions: Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Interventions: FARAPOINT Pulsed Field Ablation System, FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System, OptiMap System (non-ablative); Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Jonesboro, Arkansas • Santa Monica, California • Athens, Georgia + 8 more

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy; Procedure · Drug · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 258
States / cities: Fairbanks, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 196 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: AZD6793, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 86
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more

Conditions: Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Interventions: BMS-986504, Carboplatin, Cisplatin, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 44
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Stress Urinary Incontinence (SUI)
Interventions: Artificial Urinary Sphincter (AUS); Device
Lead sponsor: UroMems SAS; Industry
Eligibility: 22 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 9 more

Conditions: Acromegaly
Interventions: Debio 4126, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Kidney Transplant Rejection
Interventions: Belatacept, Carfilzomib; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more

Conditions: Aortic Dissection
Interventions: GORE® Ascending Stent Graft (ASG device); Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Pyoderma Gangrenosum
Interventions: Placebo matching to spesolimab, Prednisolone, Prednisone, Spesolimab; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 23 more

Conditions: Migraine
Interventions: Placebo, Rimegepant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 27
States / cities: Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more

Conditions: Non-small Cell Lung Cancer
Interventions: Carboplatin, Cisplatin, Nivolumab, Pembrolizumab, Pemetrexed, Relatlimab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 58
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 53 more

Conditions: Primary Biliary Cholangitis
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: Not listed
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 19
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 15 more

Clinical trials in Cleveland, Ohio

Filter and sort this location

Institutions in Cleveland

Stored official records

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment